NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia

Expert Review of Hematology

Volumn 7, Issue 6, 2014, Pages 733-740

  Franchini, Massimo ^a   Lippi, Giuseppe ^b  

^a CARLO POMA HOSPITAL   (Italy)

^b Academic Hospital of Parma   (Italy)

Author keywords

Bleeding; Glanzmann's thrombasthenia; NovoSeven; Recombinant activated factor VII; Surgery

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; GLANZMANN DISEASE; HUMAN; PERIOPERATIVE PERIOD; REVIEW; THROMBOEMBOLISM; COMPLICATION; HEMORRHAGE; PROCEDURES; THROMBASTHENIA;

FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HUMANS; PERIOPERATIVE CARE; RECOMBINANT PROTEINS; THROMBASTHENIA;

EID: 84911451470     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2014.980811     Document Type: Review

References (63)

1. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006;1:10
2. Saxena R, Kannan M. Glanzmann's thrombasthenia: an overview. Clin Appl Thromb Hemost 2009;15:152-65
3. D'Andrea G, Chetta M, Margaglione M. Inherited platelet disorders: thrombocytopenias and thrombocytopathies. Blood Transfus 2009;7:278-92
4. Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost 2013;39(6):642-55
5. Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Exp Rev Hematol 2012;5(5): 487-503
6. Franchini M, Lippi G, Veneri D, et al. Inherited platelet disorders. Clin Chim Acta 2008;387:1-8
7. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010;411(1-2):1-6
8. Poon MC. Clinical Use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann' s thromboastenia. Vasc Health Risk Manag 2007;3:655-64
9. Di Minno G, Coppola A, Di Minno MN, et al. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009;102:1157-64
10. Poon MC. The Evidence of the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 2007;21: 223-36
11. TM2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost 2014;12:1244-53
12. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003;1:1138-9
13. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998;19:163-76
14. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000;7:408-13
15. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005;93: 1027-35
16. Franchini M, Crestani S, Frattini F, et al. Recombinant activated factor VII in clinical practice: a 2014 update. J Thromb Thrombolysis 2014. [Epub ahead of print]
17. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002;42:114-24
18. Uhlmann EJ, Eby CS. Recombinant activated factor VIII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004;11:198-204
19. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004;18:245-59
20. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;41:431-9
21. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG 2007;114:8-15
22. Franchini M. Recombinant factor VIIa: a review on its clinical use. Int J Hematol 2006;83:126-38
23. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011;154(8):529-40
24. Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012;3:CD005011
25. Franchini M, Crestani S, Frattini F, et al. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond. Semin Thromb Hemost 2014. [Epub ahead of print]
26. Franchini M, Franchi M, Bergamini V, et al. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost 2008;34:104-12
27. Thim L, Bjoern S, Christensen M, et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988;27:7785-93
28. Lippi G, Favaloro EJ. Laboratory hemostasis: milestones in Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med 2013;51:91-7
29. Davie EW. A brief historical review of the waterfall/cascade of blood coagulation. J Biol Chem 2003;278:50819-32
30. Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med 2007;45: 2-12
31. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011;8:502-12
32. Ovanesov MV, Panteleev MA, Sinauridze EI, et al. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis 2008;19:743-55
33. Pusateri AE, Park MS. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care 2005;9(Suppl 5):S15-24
34. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-48
35. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996;75:981-2
36. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005;3:1773-82
37. Franchini M. The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. Blood Transfus 2009;7:24-8
38. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999;82:1778
39. Poon MC, Demers C, Jobin F, et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999;94: 3951-3
40. Poon MC, d'Oiron R, Hann I, et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol 2001;38:21-5
41. Caglar K, Cetinkaya A, Aytac S, et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003;20:435-8
42. Chuansumrit A. Confirmation of high dose recombinant factor VIIa in treating patients with Glanzmann thrombasthenia. J Thromb Haemost 2003;1:396
43. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003;14:187-90
44. Almeida A, Khair K, Hann I, et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003;121:477-81
45. d'Oiron R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thromboasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-7
46. Valentino LA. Use of rFVIIa in 4 children with Glanzmann Thromboasthenia. J Pediatr Hematol Oncol 2006;28:653-8
47. Kaleelrahman M, Minford A, Parapia LA. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 2004;125: 95-6
48. Bakdash S, Lyons JM, Bastacky SI, et al. Management of persistent gastric bleeding in a patient with Glanzmann's thrombasthenia. Am J Hematol 2008;83: 411-15
49. Balci YI, Karabulut A, Kabukcu S, et al. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia. Clin Appl Thromb Hemost 2011;17:320-2
50. Caglar K, Cetinkaya A, Aytac S, et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003;20:435-8
51. Dargaud Y, Bordet JC, Trzeciak MC, et al. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006;91:ECR20
52. Lombardo VT, Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia. Clin Appl Thromb Hemost 2006;12:115-16
53. Yilmaz BT, Alioglu B, Ozyurek E, et al. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 2005;26: 843-5
54. van Buuren HR, Wielenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci 2002;47: 2134-6
55. Poon MC, D'Oiron R, Von Depka M, et al. International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group: Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004;2:1096-103
56. Giordano P, Lassandro G, Tesse R, et al. Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia. Blood Transfus 2013;11: 143-7
57. Tagliaferri A, Franchini M. The expanding role of prophylaxis with recombinant activated factor VII. Blood Transfus 2013;11:12-13
58. Lak M, Scharling B, Blemings A, et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia 2008; 14(1):103-10
59. Rajpurkar M, Chitlur M, Recht M, et al. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia 2014;20(4):464-71
60. Franchini M, Targher G, Lippi G. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2011;364:575
61. Poon MC, Zotz R, Di Minno G, et al. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006;43(1 Suppl 1):S33-6
62. Depner C, Schmid R, Kirchhoff P, et al. Perioperative management of Glanzmann's syndrome: how we did it!. Blood Coagul Fibrinolysis 2010;21:283-4
63. Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135(5):603-33